YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Late-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic "off-the-shelf" CD19-directed CAR T-cell therapy, in patients with progressive multiple sclerosis Additional presentations include P…
[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstandi…
Investing.com -- B. Riley analyst Mayank Mamtani has identified top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve's 25 basis point rate hike to 4.00%, its first increase since July 2023. The u…
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling. Continue Reading
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling. Continue Reading
TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Ther…
Arcutis Biotherapeutics, Inc. (ARQT) shares rallied 11.2% in the last trading session to close at $26.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares…
The S&P 500 fell on the Fed rate hike and hawkish Warsh comments, But AMD, Bloom Energy flirted with buy signals. Continue Reading
TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart. Continue Reading
TG Therapeutics, Inc. Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and…
It has been about a month since the last earnings report for Kymera Therapeutics, Inc. (KYMR). Shares have added about 10.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earn…
TG Therapeutics, Inc. Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman a…
TG Therapeutics is Wednesday's IBD Stock Of The Day. Shares of the multiple sclerosis biotech has topped an early entry and is near a breakout. Continue Reading
It has been about a month since the last earnings report for TG Therapeutics (TGTX). Shares have added about 15.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings relea…
[short sale] abluecup As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% of shares outstan…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. Continue Reading
Medical research and development by Gorodenkoff via Shutterstock TG Therapeutics (TGTX) shares soared on Aug 21 as speculation emerged that the biotech firm could be the target of a potential takeover. Investors cheered TGTX following an "…
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [ht…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TG Therapeutics (TGTX) drew fresh attention after reporting second quarter 2026 results, with reven…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TG Therapeutics stock has delivered a very large 3 year return, yet the valuation checks still sugg…
TG Therapeutics reported past Q2 2026 results showing revenue rising to US$240.34 million from US$141.15 million a year earlier, while net income declined to US$7.78 million and EPS came in at US$0.05, missing consensus estimates. The comp…
Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports. Continue Reading
[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * TG Therapeutics is down ~11% in Monday trading after reporting Q2 EPS that missed expectations. * Diluted EPS of $0.05 compares to $0.17 in the year-ago period. * Althoug…
TG Therapeutics TGTX reported earnings of 5 cents per share for the second quarter of 2026, missing the Zacks Consensus Estimate of 41 cents. The company had reported earnings of 17 cents per share in the year-ago quarter. Total revenues i…
Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports. Continue Reading
TG Therapeutics (TGTX) reported $240.34 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 70.3%. EPS of $0.05 for the same period compares to $0.17 a year ago. The reported revenue represents a s…
TG Therapeutics (TGTX) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring item…
TG Therapeutics, Inc. Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950…
Major earnings expected before the bell on Monday include: * Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN]) * Marriott International (MAR [https://seekingalpha.com/symbol/MAR]) * EchoStar Corporation (ECHO [https://seekingalpha.co…
* TG Therapeutics (TGTX [https://seekingalpha.com/symbol/TGTX]) is scheduled to announce Q2 earnings results on Monday, August 3rd, before market open. * The consensus EPS Estimate is $0.44 [https://seekingalpha.com/symbol/TGTX/earnings/es…
TG Therapeutics, Inc. Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3,…
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a bu…
Wall Street expects a year-over-year decline in earnings on higher revenues when Amgen (AMGN) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture…
The market expects TG Therapeutics (TGTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the compan…
TG Therapeutics is Friday's IBD Stock Of The Day after shares rebounded into a profit-taking zone on key comments from chief rival Roche. Continue Reading